Plus Therapeutics’ (PSTV) “Buy” Rating Reaffirmed at HC Wainwright

Posted by Anthony Miller on Nov 17th, 2024

Plus Therapeutics (NASDAQ:PSTV – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $8.00 price objective on the stock. HC Wainwright also issued estimates for Plus Therapeutics’ FY2028 earnings at $0.28 EPS.

Separately, Ascendiant Capital Markets lowered their price target on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd.

Get Our Latest Report on PSTV

Plus Therapeutics Trading Down 7.1 %

PSTV opened at $1.17 on Friday. The company has a market capitalization of $6.90 million, a price-to-earnings ratio of -0.37 and a beta of 0.69. Plus Therapeutics has a 12-month low of $1.15 and a 12-month high of $2.78. The business’s fifty day simple moving average is $1.40 and its 200-day simple moving average is $1.67.

Plus Therapeutics (NASDAQ:PSTV – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.71) earnings per share (EPS) for the quarter. The business had revenue of $1.28 million for the quarter. On average, equities research analysts predict that Plus Therapeutics will post -2 EPS for the current year.

Institutional Investors Weigh In On Plus Therapeutics

A hedge fund recently bought a new stake in Plus Therapeutics stock. AIGH Capital Management LLC bought a new position in Plus Therapeutics, Inc. (NASDAQ:PSTV – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned approximately 9.98% of Plus Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 3.28% of the stock is currently owned by institutional investors.

About Plus Therapeutics

(Get Free Report)

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.